RUNX1/ETO and mutant KIT both contribute to programming the transcriptional and chromatin landscape in t(8;21) AML
收藏NIAID Data Ecosystem2026-03-12 收录
官方服务：
资源简介：
This SuperSeries is composed of the SubSeries listed below. Refer to individual Series
应用场景：
创建时间：
2021-07-01
相关数据集
Additional file 7 of FBXO22 promotes leukemogenesis by targeting BACH1 in MLL-rearranged acute myeloid leukemia
Additional file 7. Table S2. Mass spectrometry data
Figshare2024-02-07 更新50
Identification and interrogation of the gene regulatory network of CEBPA double mutant Acute Myeloid Leukaemia [KO52 ATAC-seq]. Identification and interrogation of the gene regulatory network of CEBPA double mutant Acute Myeloid Leukaemia [KO52 ATAC-seq]
Acute myeloid leukaemia (AML) is a heterogeneous haematological malignancy caused by mutations in genes encoding transcriptional and epigenetic regulators together with signalling genes. It is charact
NIAID Data Ecosystem20
Global Identification of the miR-130a targetome in human HSPC Reveals a Novel Role for TBL1XR1 in Hematopoietic Stem Cell Self-Renewal and t(8;21) AML
Gene expression profiling and proteome analysis of normal and malignant hematopoietic stem cells (HSC) point to shared core stemness properties. However, discordance between mRNA and protein signature
NIAID Data Ecosystem10
Gene expression changes in THP1 AML cells following Withaferin A exposure. Gene expression changes in THP1 AML cells following Withaferin A exposure
Connectivity map analysis using an AML-specific cMYB gene signature (Walf-Vorderwulbecke et al. Leukemia. 2018;32(4):882-889. 10.1038/leu.2017.317) identified withaferin A (WFA) as a candidate cMYB de
NIAID Data Ecosystem20
CITE-seq (cellular indexing of transcriptomes and epitopes by sequencing) of WT and RAS mutant specimens from acute myeloid leukemia (AML) patients.. CITE-seq (cellular indexing of transcriptomes and epitopes by sequencing) of WT and RAS mutant specimens from acute myeloid leukemia (AML) patients.
To understand the role of RAS mutations in AML, we performed CITE-seq on diagnosis specimens from WT and RAS mutant AML patients. Overall design: Cells were harvested from AML patients at diagnosis an
NIAID Data Ecosystem10
